These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 23528414

  • 1. Opinion on adventitious agents testing for vaccines: why do we worry so much about adventitious agents in vaccines?
    Sheets RL.
    Vaccine; 2013 Jun 10; 31(26):2791-5. PubMed ID: 23528414
    [Abstract] [Full Text] [Related]

  • 2. Overview of current preclinical testing strategies for viral vaccines.
    Wood DJ.
    Dev Biol Stand; 1998 Jun 10; 95():19-23. PubMed ID: 9855410
    [No Abstract] [Full Text] [Related]

  • 3. Adventitious agents in viral vaccines: lessons learned from 4 case studies.
    Petricciani J, Sheets R, Griffiths E, Knezevic I.
    Biologicals; 2014 Sep 10; 42(5):223-36. PubMed ID: 25135887
    [Abstract] [Full Text] [Related]

  • 4. Safety assessment of biotechnology-derived pharmaceuticals: ICH and beyond.
    Serabian MA, Pilaro AM.
    Toxicol Pathol; 1999 Sep 10; 27(1):27-31. PubMed ID: 10367669
    [Abstract] [Full Text] [Related]

  • 5. Systematic evaluation of in vitro and in vivo adventitious virus assays for the detection of viral contamination of cell banks and biological products.
    Gombold J, Karakasidis S, Niksa P, Podczasy J, Neumann K, Richardson J, Sane N, Johnson-Leva R, Randolph V, Sadoff J, Minor P, Schmidt A, Duncan P, Sheets RL.
    Vaccine; 2014 May 19; 32(24):2916-26. PubMed ID: 24681273
    [Abstract] [Full Text] [Related]

  • 6. Adventitious agents and live viral vectored vaccines: Considerations for archiving samples of biological materials for retrospective analysis.
    Klug B, Robertson JS, Condit RC, Seligman SJ, Laderoute MP, Sheets R, Williamson AL, Gurwith M, Kochhar S, Chapman L, Carbery B, Mac LM, Chen RT, Brighton Collaboration Viral Vaccine Vector Safety Working Group. Electronic address: brightoncollaborationv3swg@gmail.com.
    Vaccine; 2016 Dec 12; 34(51):6617-6625. PubMed ID: 27317264
    [Abstract] [Full Text] [Related]

  • 7. Current testing methods and challenges for detection of adventitious viruses.
    Khan AS.
    PDA J Pharm Sci Technol; 2011 Dec 12; 65(6):627-33. PubMed ID: 22294589
    [Abstract] [Full Text] [Related]

  • 8. Viral safety and extraneous agents testing for veterinary vaccines.
    Dodet B, Hesselink W, Jungbäck C, Léchenet J, Pastoret PP, Vannier P, Vicari M.
    Biologicals; 2010 May 12; 38(3):326-31. PubMed ID: 20503495
    [No Abstract] [Full Text] [Related]

  • 9. Evolution of approaches to viral safety issues for biological products.
    Lubiniecki AS.
    PDA J Pharm Sci Technol; 2011 May 12; 65(6):547-56. PubMed ID: 22294576
    [Abstract] [Full Text] [Related]

  • 10. Adventitious agents and vaccines.
    Krause PR.
    Emerg Infect Dis; 2001 May 12; 7(3 Suppl):562. PubMed ID: 11485673
    [No Abstract] [Full Text] [Related]

  • 11. Application of Risk Assessments in the Design of the Overall Viral Control Strategy Used during the Manufacture and Testing of Live Virus Vaccines.
    Pennathur S.
    PDA J Pharm Sci Technol; 2011 May 12; 65(6):730-6. PubMed ID: 22294607
    [Abstract] [Full Text] [Related]

  • 12. Extraneous agents testing for substrates of avian origin and viral vaccines for poultry: current provisions and proposals for future approaches.
    Jungbäck C, Motitschke A.
    Biologicals; 2010 May 12; 38(3):362-5. PubMed ID: 20335053
    [Abstract] [Full Text] [Related]

  • 13. Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) standardized template for collection of key information for benefit-risk assessment of live-attenuated viral vaccines.
    Gurwith M, Condit RC, Excler JL, Robertson JS, Kim D, Fast PE, Drew S, Wood D, Klug B, Whelan M, Mallett Moore T, Khuri-Bulos N, Smith ER, Chen RT, Kochhar S, Brighton Collaboration Viral Vector Vaccines Safety Working Group V3SWG.
    Vaccine; 2020 Nov 17; 38(49):7702-7707. PubMed ID: 33070999
    [Abstract] [Full Text] [Related]

  • 14. Issues of biological assays for viral vaccines.
    Lee CK.
    Dev Biol Stand; 1996 Nov 17; 88():41-7. PubMed ID: 9119161
    [Abstract] [Full Text] [Related]

  • 15. Adventitious agent test methods.
    Sheets RL.
    Dev Biol (Basel); 2006 Nov 17; 123():135-45; discussion 183-97. PubMed ID: 16566441
    [No Abstract] [Full Text] [Related]

  • 16. [Detection of the adventitious agents in the evaluation of vaccine safety].
    Augustynowicz E, Lutyńska A.
    Przegl Epidemiol; 2012 Nov 17; 66(4):643-9. PubMed ID: 23484394
    [Abstract] [Full Text] [Related]

  • 17. Process evaluation for biopharmaceuticals: what is appropriate in process evaluation?
    Lubiniecki AS, McAllister PR, Smith TM, Shadle PJ.
    Dev Biol Stand; 1996 Nov 17; 88():309-15. PubMed ID: 9119154
    [No Abstract] [Full Text] [Related]

  • 18. Human and animal vaccine contaminations.
    Pastoret PP.
    Biologicals; 2010 May 17; 38(3):332-4. PubMed ID: 20456974
    [Abstract] [Full Text] [Related]

  • 19. The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccines.
    Condit RC, Kim D, Robertson JS, Excler JL, Gurwith M, Monath TP, Pavlakis G, Fast PE, Smith J, Smith ER, Chen RT, Kochhar S, Brighton Collaboration Benefit-Risk Assessment of Vaccines by Technology (BRAVATO) Working Group. Electronic address: bc-coordinator@taskforce.org.
    Vaccine; 2020 Nov 17; 38(49):7708-7715. PubMed ID: 32907759
    [Abstract] [Full Text] [Related]

  • 20. Ensuring the quality, potency and safety of vaccines during preclinical development.
    Lebron JA, Wolf JJ, Kaplanski CV, Ledwith BJ.
    Expert Rev Vaccines; 2005 Dec 17; 4(6):855-66. PubMed ID: 16372881
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.